Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Leukemia Research|March 7, 2014
Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusionsRui Cui, Robert Peter Gale, Guoqing Zhu, et al.
Blood Cancer Journal|January 17, 2018
Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia responseXueping Luo, Zefeng Xu, Bing Li, et al.
Frontiers in Immunology|May 4, 2026
The profile of clinical and laboratory features of Chinese VEXAS syndrome patients with hematological abnormalities: a single-center case seriesXiang Ren, Min Wang, Jiali Huo, et al.
Oncotarget|December 2, 2016
Multiplex ligation-dependent probe amplification assay identifies additional copy number changes compared with R-band karyotype and provide more accuracy prognostic information in myelodysplastic syndromesJingya Wang, Xiaofei Ai, Tiejun Qin, et al.
Stem Cell Investigation|October 26, 2016
TET2 mutations were predictive of inferior prognosis in the presence of ASXL1 mutations in patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Experimental Hematology & Oncology|April 30, 2016
A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromesGege Feng, Robert Peter Gale, Wen Cui, et al.
Experimental Hematology & Oncology|May 29, 2015
Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemiaYajuan Cui, Hongyan Tong, Xin Du, et al.
Cell Reports. Medicine|March 27, 2025
KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemiaLele Zhang, Chen Qiu, Ruonan Li, et al.
Frontiers in Immunology|February 16, 2026
Low-dose cyclophosphamide combined with standard immunosuppressive therapy improves early response rates in severe aplastic anemiaHong Pan, Zhen Gao, Lele Zhang, et al.
American Journal of Hematology|January 5, 2026
Hetrombopag Added to Cyclosporine as the First-Line Treatment for Patients With Non-Severe Aplastic Anemia: A Phase 2 Multicenter TrialLele Zhang, Ruonan Li, Qian Liang, et al.
Pageof 8